Home › Funds › Citigroup Inc › ABUS
Citigroup Inc position in ABUS
ARBUTUS BIOPHARMA CORP · Health Care
Latest position (Q2 2026)879.24K sh
Reported value held$4.22M
Portfolio Weight0.00%
First reportedQ3 2021
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 14.68K | $63.00K | New |
| Q4 2021 | 24.65K | $96.00K | Add |
| Q1 2022 | 30.99K | $92.00K | Add |
| Q2 2022 | 9.60K | $26.00K | Reduce |
| Q3 2022 | 3.43K | $7.00K | Reduce |
| Q4 2022 | 2.77K | $6.46K | Reduce |
| Q1 2023 | 285.28K | $864.40K | Add |
| Q2 2023 | 550.06K | $1.27M | Add |
| Q3 2023 | 527.66K | $1.07M | Reduce |
| Q4 2023 | 879.68K | $2.20M | Add |
| Q1 2024 | 696.89K | $1.80M | Reduce |
| Q2 2024 | 1.71M | $5.29M | Add |
| Q3 2024 | 743.85K | $2.86M | Reduce |
| Q4 2024 | 487.72K | $1.59M | Reduce |
| Q1 2025 | 821.64K | $2.87M | Add |
| Q2 2025 | 884.61K | $2.73M | Add |
| Q3 2025 | 1.48M | $6.73M | Add |
| Q4 2025 | 1.57M | $7.55M | Add |
| Q1 2026 | 1.33M | $5.98M | Reduce |
| Q2 2026 | 879.24K | $4.22M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding ABUS
- Morgan Stanley 17.70M sh · $84.95M · Q2 2026
- BlackRock Inc 13.77M sh · $66.08M · Q2 2026
- Vanguard Group 9.24M sh · $44.46M · Q4 2025
- Geode Capital Management 4.12M sh · $19.77M · Q2 2026
- Goldman Sachs Group 3.51M sh · $16.83M · Q2 2026
- Bank of America Corp 2.65M sh · $12.70M · Q2 2026
- Legal & General Investment Management America 2.47M sh · $11.84M · Q2 2026
- Charles Schwab Investment Management 1.43M sh · $6.87M · Q2 2026
- Northern Trust Corp 1.42M sh · $6.81M · Q2 2026
- Arrowstreet Capital 650.70K sh · $3.12M · Q2 2026
- Wellington Management Group 461.65K sh · $2.22M · Q2 2026